Middle East Healthcare Co. (Saudi German Health) (4009) — Financial Analysis & Intrinsic Value · TASIV

Middle East Healthcare Co. (Saudi German Health) intrinsic value and dividend analysis using DCF, P/B, PEG and PSG models. Includes dividend yield, payout ratio, and dividend sustainability assessment. Sector: Health Care Equipment & Svc. Listed on Saudi Exchange Tadawul.

Company Overview

Middle East Healthcare Company owns and operates a network of hospitals under the Saudi German Hospital name in Saudi Arabia and internationally. It also manages medical, educational, rehabilitation, laboratory, and radiology centers, and pharmacies. Founded in 1988 and based in Jeddah, the company is a subsidiary of Bait Al Batterjee Medical Co. Ltd.

Valuation Model

TASIV estimates this company's intrinsic value using a DCF (Discounted Cash Flow) model. As of TASIV's most recent data refresh, the estimated intrinsic value is SAR 69.19 compared to a market price of SAR 31.98 (Trading significantly below DCF model value). This is an analytical estimate, not investment advice.

Financial Performance

Revenue increased by about 17% over the three-year period, while net income grew at a much faster rate of approximately 68%, indicating that profitability increased considerably faster than sales. Operating cash flow increased even more sharply, up by about 185% overall, after a large jump in the second year that partly eased in the third, outpacing the growth seen in both revenue and net income. Overall, the company's historical financial performance shows growth across all three measures, with cash generation increasing the most and revenue growing the least.

Dividends

Over the 5 years on record, dividend per share fell in each period, moving from SAR 2 to SAR 0.5 — a decline of about 75%. Payments have been made on an Annual basis throughout this period. The company's per-share dividend has declined steadily across the recorded period. Current dividend yield is approximately 1.56%, with a payout ratio of approximately 15.24%.

Business Fundamentals

TASIV's Competitive Advantage assessment for this company is High (76/100), based on profitability, predictability, financial strength, and growth resilience.

Similar Companies in This Sector

Frequently Asked Questions

What is the estimated intrinsic value of Middle East Healthcare Co. (Saudi German Health) (4009) according to TASIV's model?

Based on TASIV's DCF (Discounted Cash Flow) model, the estimated intrinsic value of Middle East Healthcare Co. (Saudi German Health) is approximately SAR 69.19, compared to a current market price of SAR 31.98. This is an analytical estimate based on the company's financial data, not investment advice or a recommendation to buy or sell.

How does Middle East Healthcare Co. (Saudi German Health)'s current market price compare to TASIV's model value?

According to TASIV's model, Middle East Healthcare Co. (Saudi German Health) is currently "Trading significantly below DCF model value".

What is the dividend yield for Middle East Healthcare Co. (Saudi German Health) (4009)?

Middle East Healthcare Co. (Saudi German Health)'s dividend yield is approximately 1.56%, with a payout ratio of approximately 15.24%, based on TASIV's most recent verified data.

Loading 4009...